June 8, 2023: Endocrine Disruption Litigation Has Arrived
In their latest article for Carrier Management, Praedicat’s David Loughran and Adam Grossman explore the emergence of endocrine disruption as a major concern, with recent litigations involving hair relaxer products and acetaminophen.
While courts have yet to determine the acceptance of endocrine disruption as a mechanism for compensable bodily injury, the precedents established in the hair relaxer and acetaminophen litigations will provide insights into future endocrine disruption litigations.
Read the full article here.
Insider Engage – PFAS the mother of all toxic torts?
Praedicat Blog – The Past, Present, and Future of PFAS Litigation in the US
Praedicat Update – PFAS in Drinking Water Scenarios
Get in touch with one of our Account Manager team members.
Sign up here to receive the latest news, insights, event notifications, and information from Praedicat.
Learn more about Praedicat and our a company risk score, Litigation Tracker, Lloyd’s liability scenario solution, emerging risk framework, COVID-19 offerings, as well as our collaboration with AON Reinsurance Solutions.